CELLINK announces an increase in number of shares and votes

The number of shares and votes in CELLINK AB (publ) has increased as a result of a new issue of 1,625,000 shares of series B that the Board of Directors resolved on August 20, 2020 and that the extra general meeting approved on September 11, 2020. The number of shares and votes in CELLINK has also increased as a result of a non-cash share issue of 2,814,032 shares of series B. The non-cash share issue was made to finance the acquisition of Scienion Ag. As a result of the new issues the number of shares and votes in the company was increased by a total of 4,439,032.

As of September 30, 2020, the total number of registered and outstanding shares of CELLINK amounts to 51,601,285, of which 1,500,000 are shares of series A and 50,101,285 are shares of series B, corresponding to a total of 65,101,285 votes. The share capital amounts to SEK 1,290,032.125. The company does not hold any treasury shares.

For further information, please contact:

Erik Gatenholm, CEO                                                            Gusten Danielsson, CFO

Phone (Sweden): +46 73 267 00 00                                       Phone (Sweden): +46 70 991 86 04

Phone (US): +1 (650) 515 5566                                             Phone (US): +1 (857) 332 2138

Email: eg@cellink.com                                                            Email: gd@cellink.com

This is information that CELLINK AB (publ) is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication, through the agency of the contact persons set out above, on September 30, 2020 at 08:45 a.m. (CEST).


CELLINK is a global life-science company providing technologies, products, and services to create, understand, and master cell and molecular biology, with a focus on three main application areas: bioprinting, analysis, and liquid handling & bioprocessing. The company develops and markets innovative cell culture technologies, enabling researchers in the life sciences to print human organs and tissues for pharmaceutical and cosmetic applications. Founded in 2016, CELLINK’s products have been adopted by researchers and scientists in more than 1,000 laboratories with more than 100 publication citations, the majority of the largest pharmaceutical companies and has been delivered to more than 55 countries around the world. The company’s vision is to create the future of medicine.

Visit www.cellink.com to learn more. CELLINK is listed on Nasdaq Stockholm Main Market under CLNK B.

Latest press releases